Business Context and Reporting Period
Company: Abbott Laboratories
Filing Type: Form 8-K (Current Report)
Date of Report: April 20, 2016
Reporting Period: First Quarter 2016
This filing announces the results of operations for the first quarter of 2016. The detailed financial data is contained in a press release furnished as Exhibit 99.1 and incorporated by reference.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are located in the referenced Exhibit 99.1 (Press Release).
The company utilizes non-GAAP financial measures to assess performance, specifically:
- Net earnings from continuing operations excluding specified items.
- Adjustments for unusual or unpredictable factors, including foreign exchange losses related to Venezuela, cost reduction initiatives, transaction-related costs, and tax position resolutions.
- Exclusion of intangible amortization expense to align with internal management assessments.
Material Changes
The filing text does not explicitly detail material changes versus the prior comparable period. It notes that the non-GAAP measures adjust for specific items such as the foreign exchange loss related to Venezuela and various tax adjustments, implying these were significant factors in the period's results.
Guidance, Outlook, and Risks
Management Commentary: Management believes the presentation of non-GAAP measures provides useful information for evaluating ongoing business performance and is used internally to monitor business units. However, the company cautions investors to consider these measures in addition to, and not as a substitute for, GAAP financial measures.
Risks and Contingencies: The filing highlights specific items excluded from non-GAAP calculations that represent risks or unusual events, including:
- Foreign exchange losses (specifically Venezuela).
- Cost reduction initiatives.
- Transaction-related costs.
- Resolution of tax positions and adjustments of tax uncertainties from prior years.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific GAAP and non-GAAP revenue, earnings, and cash flow figures.
- Verify the specific dollar impact of the foreign exchange loss related to Venezuela.
- Confirm the magnitude of transaction-related costs and tax adjustments excluded from non-GAAP results.
- Compare the reported non-GAAP margins against GAAP margins to understand the impact of intangible amortization.